Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Acquisitions & Divestments (2018 - 2025)

UroGen Pharma (URGN) has disclosed Change in Acquisitions & Divestments for 8 consecutive years, with $28.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments fell 59.59% year-over-year to $28.3 million, compared with a TTM value of $139.2 million through Dec 2025, up 29.29%, and an annual FY2025 reading of $139.2 million, up 29.29% over the prior year.
  • Change in Acquisitions & Divestments was $28.3 million for Q4 2025 at UroGen Pharma, down from $40.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $70.0 million in Q4 2024 and bottomed at -$42.2 million in Q4 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $18.1 million, with a median of $14.5 million recorded in 2021.
  • The sharpest move saw Change in Acquisitions & Divestments crashed 184.94% in 2021, then skyrocketed 4344.32% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at -$42.2 million in 2021, then surged by 154.84% to $23.1 million in 2022, then plummeted by 84.71% to $3.5 million in 2023, then soared by 1879.21% to $70.0 million in 2024, then crashed by 59.59% to $28.3 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for URGN at $28.3 million in Q4 2025, $40.2 million in Q3 2025, and $30.3 million in Q2 2025.